Viewing Study NCT01113333


Ignite Creation Date: 2025-12-25 @ 2:53 AM
Ignite Modification Date: 2025-12-31 @ 2:52 AM
Study NCT ID: NCT01113333
Status: COMPLETED
Last Update Posted: 2011-03-23
First Post: 2010-04-23
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety, Tolerability and Pharmacokinetics of SAR113945 Following Intra-articular Administration in Patients With Knee Osteoarthritis
Sponsor: Sanofi
Organization:

Study Overview

Official Title: A Double Blind, Placebo Controlled Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the IKK Inhibitor, SAR113945, Following Intra-articular Administration in Patients With Knee Osteoarthritis
Status: COMPLETED
Status Verified Date: 2011-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Primary Objective:

* Assess the safety and tolerability of single intra-articular doses of SAR113945 in patients with knee osteoarthritis.

Secondary Objective:

* Assess systemic exposure of SAR113945 following intra-articular delivery.
Detailed Description: The total study duration per subject ranges from 4 to 20 weeks broken down as follows:

* screening within 4 weeks before dosing,
* follow-up of 4 weeks (28 days) after the single dose of study medication,
* prolonged by a maximum of 12 weeks if plasma PK level \> Limit Of Quantification (LOQ) at Day 28.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2009-017502-36 EUDRACT_NUMBER None View
U1111-1116-5630 OTHER UTN View